Semaglutide as a GLP-1 receptor agonist: the evidence behind Wegovy

What activating the GLP-1 receptor actually does in the body

GLP-1 is released from cells lining the small intestine shortly after a meal. It acts on receptors in the pancreas, the gut wall, and (crucially) in areas of the brain involved in appetite and reward. Semaglutide is an analogue of this hormone, engineered to last far longer in the bloodstream than the natural molecule, which is broken down within minutes. That extended half-life is what allows once-weekly injection, or once-daily tablet dosing with the newer oral formulation.

When semaglutide binds to GLP-1 receptors, it triggers a cascade of effects: the stomach empties more slowly, so a smaller meal produces a more sustained sense of fullness; appetite signals from the hypothalamus are reduced, meaning hunger returns less forcefully between meals; and insulin secretion is stimulated in a glucose-dependent way, which is why hypoglycaemia is not typically a risk in people without diabetes.

If you are curious about whether semaglutide is a GLP-1 agonist and what that means for how it works, our dedicated page covers the classification in plain terms. For a deeper dive, you can also read about how semaglutide works as a GLP-1 receptor agonist and what that classification means at a molecular level, our detailed look at its receptor pharmacology goes further into the mechanism. The short version: semaglutide is a single-pathway agonist, acting only on GLP-1 receptors, which distinguishes it from tirzepatide, which acts on both GLP-1 and GIP receptors. You can read more about whether Wegovy is a dual agonist and what the difference means in practice.

Understanding the mechanism matters practically, not just academically. The same receptor activity that drives weight loss also explains why starting slowly (at 0.25mg) helps the digestive system adjust before the dose climbs.

What the STEP 1 trial established, and how the Wegovy 7.2mg approval builds on it

The foundational evidence for semaglutide as a weight-management medicine comes from the STEP programme, a series of phase 3 trials. STEP 1, involving adults with obesity or overweight and at least one weight-related condition but without type 2 diabetes, found average weight loss of roughly 15% over 68 weeks at the 2.4mg weekly dose, more than double what had been seen in earlier pharmacotherapy trials for weight management. NICE reviewed this evidence when it published its recommendation for Wegovy (TA875), concluding it was cost-effective for use within specialist weight management services for eligible adults.

Since then, the picture has continued to move. The MHRA approved a 7.2mg dose of Wegovy in January 2026, initially delivered as three 2.4mg pens weekly, with trials reporting average weight loss of around 20.7% over 72 weeks at that dose, narrowing the gap with tirzepatide's headline figures from the SURMOUNT-1 trial. A dedicated single-dose 7.2mg pen was then approved on 14 April 2026. These are not small refinements; they represent a meaningful upward revision of what GLP-1 agonist Wegovy can achieve at its highest licensed dose.

For a fuller picture of how semaglutide's results stack up in clinical studies, our semaglutide overview page covers the evidence across the STEP programme in plain language.

Who semaglutide-based treatment is licensed for, and how that shapes private access

Wegovy's UK licence covers adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related health condition such as raised blood pressure, high cholesterol, or prediabetes. Lower BMI thresholds apply for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds under UK guidance. That licence applies to both the injection and the oral tablet formulation approved in June 2026.

The NICE recommendation for the injection (TA875) adds further conditions for NHS access: use within a specialist weight management service, for a maximum of two years, with multidisciplinary support. NHS waiting lists for specialist services are often long, and not everyone who is licensed for the medicine will meet the NHS commissioning thresholds at this stage of the phased rollout. Private prescription through a regulated pharmacy is the alternative route for people who are clinically eligible but prefer not to wait.

Before thinking about cost, it is worth spending sixty seconds checking whether a pharmacy you are considering appears on the GPhC register at pharmacyregulation.org/registers, that single check confirms whether a pharmacy is legally registered to dispense prescription medicines in the UK. For context on what private Wegovy treatment typically costs, our Wegovy pricing page sets out the market picture honestly. Our treatment overview covers both Wegovy and the other options our prescribers can consider.

Side effects linked to GLP-1 receptor activation

Because semaglutide works through the same receptor system as a gut hormone, its side-effect profile is largely gastrointestinal. Nausea is the most commonly reported effect, particularly in the early weeks and after each dose increase. Vomiting, loose stools, constipation, indigestion, and burping are also common. Most people find these settle within days to a couple of weeks as the body adapts; the gradual titration schedule exists partly to reduce their intensity.

Less commonly, some people experience fatigue, headache, or dizziness. The slow titration and the option to pause at any dose level are there precisely to manage this, a prescriber, not the patient alone, makes those calls.

More serious but infrequent effects linked to GLP-1 medicines include acute pancreatitis. Persistent, severe stomach pain that radiates toward the back, with or without vomiting, needs prompt medical attention, the MHRA's Yellow Card scheme is where suspected side effects can be reported. Semaglutide is not recommended in pregnancy, while breastfeeding, or for people trying to conceive, and it is not licensed for anyone under 18.

If you have questions about how the GLP-1 mechanism compares across different medicines, or whether semaglutide's single-pathway action is right for your situation, our prescribers are the right people to ask. Check your eligibility with a free consultation, reviewed the same day by a GPhC-registered Independent Prescriber.